Italian newspaper La Stampa quoted sources from the Ministry of Health today as saying that the European Commission has decided not to renew vaccine supply contracts with AstraZeneca and Johnson & Johnson next year.
The document pointed out that the European Commission has reached a consensus with EU leaders to decide and produce the so-called “vector vaccine will not regenerate after it expires.”
The reason for the European Commission’s decision is not yet known, but the dispute between AstraZeneca and the European Union over the extension of the vaccine has been going on for several months, and there are suspicions of side effects between the vaccine and Johnson & Johnson. , In rare cases may cause blood clots.
The document pointed out that Europe will replace the so-called vector vaccine with a focus on vaccines that use modern mRNA technology, such as Pfizer and modern vaccines.
Reuters reminded that the European Commission is still asking Johnson & Johnson for an explanation for delaying the delivery of vaccines to the EU.